Momenta Shelves Adalimumab But Persists With Aflibercept

 
• By Aidan Fry

Having failed to find a commercial partner, Momenta has halted development on its adalimumab biosimilar. But it is continuing to work on biosimilar aflibercept in conjunction with partner Mylan.

old books on the shelf - Image
Commercial considerations have led Momenta to shelve active development on its M923 adalimumab candidate • Source: Shutterstock

More from Biosimilars

More from Products